Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Chronic Diseases > Diabetes x2 > Flashcards

Diabetes x2 Flashcards

1
Q

Screening for DM for patient’s <40 with no risk factors

A

no screening required

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Screening for DM for patients > 40 yo

A

q3y

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Screening for DM for patients at high risk

A

q6-12mon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

If a patient is prediabetic, what 3 things would you want to implement

A

weight loss (5-7% of initial weight)
Physical activity 150min/week as this decreases the risk of progression by 60%
mediterranean diet
DASH diet
Metformin 850 mg PO BID, as it decreases risk of progression by 30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the important pieces of care for DM pt

A

A1C under good control (<7)
Blood pressure target <130/<80
Cholesterol target - may need a statin
Drugs to reduce risk of CVD (statin, acei/arb, sglt2i, glp1)
exercise - 150min aerobic/week, 2-3 days of resistance training
eating better
screening - feet, eyes, kidneys, heart
smoking cessation
sick day management (for metformin, insulin, SGLT2i)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

If pt has an elevated A1C 7.5, what would you do initially for management

A

trial lifestyle modifications for 3 months, before starting metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

If a patient has an elevated A1C 10, what you do

A

start metformin right away

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

If patient has symptomatic hyperglycemia or metabolic decompensation

A

insulin +/- metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Name all of the SGLT2i

A

Empagliflozin (jardiance)
Canagliflozin (Invokana)
Dapagliflozin (Farxiga)
Bexagliflozin (Brenzavvy)
Ertugliflozin (steglatro)
Sortagliflozin (Inpefa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Brand name for empagliflozin & class

A

jardiance & SGLT2i

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Brand name for dapagliflozin & class

A

forxiga & SGLT2i

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Brand name for canagliflozin & class

A

invokana & SGLT2i

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Brand name for bexagliflozin & class

A

brenzavvy & SGLT2i

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Brand name for ertugliflozin & class

A

steglatro & SGLT2i

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Brand name for sortiglaflozin & class

A

inpefa & SGLT2i

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Name the GLP1 agonists

A

Semaglutide (Ozempic)
Liraglutide (Victoza)
Dulaglutide (Trulicity)
Exenatide (Byetta)
Lixisenatide (Adlyxine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Brand name for semaglutide & its class

A

ozempic & GLP1 agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Brand name for liraglutide & class

A

Victoza & GLP1 agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Brand name for Dulaglutide & class

A

Trulicity & GLP1 agonist

20
Q

Brand name for Exenatide & class

A

Byetta

21
Q

Brand name for Lixisenatide & class

A

Adlyxine

22
Q

Name the DDP (Dipeptidyl peptidase 4 inhibitors)

A

Alogliptin (Nesina)
Linagliptan (Tradjenta)
Saxagliptin (Onglyza)
Sitagliptin (Januvia)

23
Q

Brand name and class for linagliptin

A

tradjenta & DPP4i

24
Q

Brand name and class for sitagliptin

A

januvia & DPP4i

25
Q

Brand name and class for saxagliptin

A

onglyza & DPP4i

26
Q

Brand name and class for alogliptin

A

Nesina & DPP4i

27
Q

Mechanism of action for SGLT2i & adverse effects

A

Inhibits the sodium glucose transporter in the proximal renal tubules, reduces the reabsorption of glucose (as SGLT2 is the main site of glucose reabsorption) therefore increasing urinary output of glucose

Increased urinary frequency
Genital mycotic infection
UTI
Euglycemic DKA
AKI
hyperK

28
Q

What is the mechanism of SGLT2i on sodium in the body

A

Reduces Na reabsorption, means there is more Na present in the distal renal tubule, which may lower pre and afterload on heat & downregulate sympathetic activity

29
Q

Mechanism of action for GLP1 agonists & adverse effects

A

Selectively bind to GLP1 receptor, then increases insulin secretion, decreases inappropriate glucagon secretion, slows gastric emptying, acts in areas of brain involved in regulation of appetite and calorie intake.

Nausea, vomiting, diarrhea
AKI - bc volume contraction
Gallbladder disease (cholelithiasis and/or cholecystitis) [ occur more in pt w/ rapid weight loss, higher doses >1mg, longer duration tx >26 weeks]
increase risk of it pancreatitis (not to be used in pt w/ hx)
?risk of medullary thyroid carcinoma (not to be used in patients w/ fam hx of it OR hx MEN2 [multiple endocrine neoplasia syndrome type 2]

30
Q

Mechanism of action for DPP4 inhibitors & adverse effects

A

Inhibits the DDP4 enzyme, which prolongs incretin level, which increases insulin synthesis and release from pancreatic beta cells and decreases glucagon secretion from pancreatic alpha cells (also means decreased glucose production)

Generally well tolerated, does seem to cause arthralgia, pancreatitis, CHF and maybe pancreatic cancer

31
Q

Diabetic agents that can cause hypoglycemia

A

Sulfonylurea
- Glyburide > gliclazide

32
Q

Which diabetic agents are once daily dosing

A

sulfonylureas (gliclazide, glyburide)
Pioglitazone (thiazolidinedione)
SGLT2i (empagliflozin, dapagliflozin, canagliflozin)
DPP4i (sitagliptin, linagliptin)
Oral GLP1 agonists (semaglutide)
Metformin ER
Janumet (DPP4i/metformin)

33
Q

Which diabetic agents are once weekly options

A

semaglutide (ozempic subcut)
dulaglutide (trulicity subcut)

34
Q

Which diabetic agents have been shown to prevent major complications in patients with cardiovascular disease

A

SGLT2i (dapagliflozin - Forxiga, empagliflozin - Jardiance, canagliflozin - Invokana)
GLP1 agonists (semaglutide - ozempic, dulaglutide - trulicity, liraglutide - victoza)

35
Q

Which diabetic agents have been shown to prevent major complications in patients with nephropathy

A

SGLT2i (canagliflozin - Invokana, dapagliflozin - Forxiga, empagliflosin - Jardiance)

36
Q

Which diabetic agents have been shown to prevent major complications in patients with HFrEF

A

SGLT2i (cangliflozin - invokana, empagliflozin - jardiance, dapagliflozin - forxiga)

37
Q

In pregnancy, what diabetic agents are safe to use

A

Insulin
Metformin
?glyburide (not initial alternative tx choice, does cross the placenta and no long term safety data available)
BUT gliclazide is contraindicated in pregnancy

38
Q

What diabetic agents are appropriate to be used in patients who have renal dysfunction?

A

Insulin
DPP4i (linagliptin - tradjenta, sitagliptin - januvia)
GLP1 agonists (semaglutide - ozempic, dulaglutide - trulicity, liraglutide - victoza)

39
Q

Which agents also cause weight loss

A

GLP1 agonists > SGLT2i > metformin >DPP4

40
Q

Which diabetic agents can cause weight gain

A

insulin
sulfonylureas
thiazolidinedione
repaglinide

41
Q

Which is better for people w/ DM, ACEI or ARB

A

Appear to be equally effective for cardiorenal protection. Have a reduction in the risk and progression of CKD independent of its effect on their BP. Target CV protective doses: ramipril 10 mg, telmisartan 80 mg, perindopril 8 mg

42
Q

Do all patients w/ DM need an ACEI or ARB

A

Not all but many. No studies have shown a CV benefit for ACEI/ARBs in patients without HTN or CVD. No evidence for using ACEI/ARBs for primary prevention of nephropathy in patients with normal renal function. However, the majority of pts with DM have additional indications for ACEI/ARBs: clinical CVD, > 55 yo with additional risk factors or end organ damage (ACR > 2, retinopathy, LVH) or microvascular complications. ALL patients with DM and CKD with either HTN or albuminuria ACR >30 mg/g should be on an ACEI/ARB to delay progression of CKD.

43
Q

Why do ACEI/ARBs protect the kidneys but can also cause acute kidney injury?

A

During periods of illness (dehydrated), RAAS blockers can reduce kidney function bc interfere w/ kidneys response to intravascular volume depletion by decreasing ability of ANGII to support gfr leading to inadequate perfusion. Monitor serum Cr and K+ at baseline at baseline and 1-2 weeks after starting or increasing dose. A transient increase in serum Cr is normal and should stabilize over time. It is concerning if sCr >30% baseline, should stop the ACEI/ARB. Be aware of sick days to hold these meds when dehydrates and avoid NSAIDs

44
Q

Do all patients with DM need a statin (primary prevention)

A

Not all but many. Consider it in all adults w/ T1DM and T2DM, with at least 1 of the following: >40 yo, or 30-40 yo + DM for >15 y, or microvascular complications. Treatment with statin decreases CV risk and CVA events over 4 years, even when the initial LDL was already <3. Best evidence is for moderate doses, atorvastatin 10 mg, simvastatin 40 mg

45
Q

If not at target or if statin intolerance, are other lipid lowering agents useful?

A

Ezetimibe has shown benefit but ONLY in combination with a statin. If a pt has familial hypercholesterolemia and unable to reach targets with combo statin + ezetimibe, can use evolocumab (PCSK9i). Fibrates and niacin are NOT recommended generally and the addition of fenofibrate to statin does not decrease risk of CV vs statin alone.

46
Q
A

Chronic Diseases (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions